Seagen Pops After Scoring A ' Must-Win ' For Its $43 Billion Pfizer Takeover
A bladder cancer treatment tied to a quartet of biopharma companies — including Pfizer (PFE) and buyout target Seagen (SGEN) — succeeded in a final-phase study on Friday, leading SGEN stock to surge. The companies added Merck's (MRK) Keytruda on top of Seagen and Astellas Pharma's (ALPMY) Padcev…#pfe #sgen #merck #seagen #astellaspharma #alpmy #isi #umerraffat #pfizer #padcev
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Health | Merck | Pfizer | Pharmaceuticals | Study